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Abstract
The aging population and the increasing number of cancer survivors will likely be associated
with more second primary malignancies due to prior cancer treatment. Since the incidence of
most cancers increases with age, these treatment-associated second malignancies will likely
disproportionately impact older adults. Here, we present the case of a 78-year-old man with
a history of localized prostate cancer treated with external beam radiation therapy 11 years
prior, who developed osteosarcoma of the ilium. Geriatric screening showed a fit older male
with few comorbidities, functional independence and no other geriatric syndromes. Given the
patient’s preference for a limb-sparing operation, neoadjuvant chemotherapy was undertaken. With the paucity of clinical trial data on osteosarcoma in older adults, the patient was
given a regimen of carboplatin (substituted for cisplatin), doxorubicin and methotrexate.
Unfortunately, he developed methotrexate-induced acute kidney injury. Chemotherapy was
discontinued, and he proceeded to hemipelvectomy. His postoperative course was marked
by numerous complications, including delirium, depression and recurrent hospitalizations. He
ultimately developed a local recurrence and elected for hospice care. This case highlights the
challenges of managing older adults with treatment-associated malignancies. Clinicians face
a lack of clinical trial data from which to extrapolate limitations of therapeutic options
because of prior therapy and a limited ability to precisely predict which elders will experience
adverse outcomes. Better approaches are needed to help older patients make decisions
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which fulfill their goals of care and to improve the care of older adults with treatmentassociated malignancies.

Introduction

Cancer is a disease of aging, with more than 60% of new cancer cases and 70% of all
cancer deaths occurring in patients older than 65 years of age [1]. Given the increasing life
expectancy, a 67% increase in cancer incidence in older patients is expected [2]. This will in
turn result in an increasing number of older adult cancer survivors and an increase in longterm consequences of cancer therapy, including treatment-associated second malignancies.
Significant gaps in the evidence on treating older patients with cancer will bring challenges in clinical decision making. Elderly cancer patients are underrepresented in clinical
trials, with only 25% of patients enrolled in clinical trials of chemotherapy over 65 years of
age [3]. Underrepresentation of older adults in clinical trials may be due to explicit age
restrictions or failure to meet eligibility criteria, but also relates to concerns that comorbidities may affect treatment response, concerns for difficulty adhering to study procedures,
concerns about toxicity, or simply the attitude of physicians, patients and their families.
Despite these perceptions, selected elderly patients may tolerate aggressive chemotherapy
and derive as much benefit from them as their younger counterparts [4]. Our ability to
reliably predict which elderly patients will do well and which will suffer severe toxicity is
limited and is the subject of ongoing research.
The changing demographics, coupled with a limited evidence base on treating cancer in
the elderly and the increasing risk of geriatric syndromes with advancing age, present
challenges in treating this population. Here we present a case study of an older patient with
a rare malignancy and highlight the challenges of treating cancer in older adults, spanning
from initial treatment decision making to the end of life.

The patient, a 78-year-old man with a history of a T1c, Gleason 8 adenocarcinoma of the
prostate treated with external beam radiation to 7,000 Gy 11 years prior, presented to us
with a slight increase in his prostate-specific antigen and pelvic pain. This prompted a bone
scan, which demonstrated uptake in the left sacroiliac joint. A CT of the abdomen and pelvis
demonstrated a mass in the lower pelvis extending from the prostate posteriorly and
laterally through the obturator fossa into the obturator externus, but no distant metastases
were found. Biopsy revealed osteosarcoma.
The patient’s past medical history included deep venous thrombosis/pulmonary embolism incidentally diagnosed during staging evaluation, prostate cancer, hypertension,
hyperlipidemia, asthma, and an episode of nephrotic syndrome 20 years prior. Geriatric
screening at the time of his initial consultation with the medical oncologist revealed that he
was independent in all of his activities of daily living (ADL) and instrumental activities of
daily living (IADL). His ambulation was limited by pain in his pelvis. He had no symptoms of
cognitive decline or depression. He reported a fall on icy pavement 5 months before
presentation. He had no incontinence. His social support was extensive, including his wife,
adult children, and grandchildren. Polypharmacy was noted, but he was on no medications
considered inappropriate in the elderly by Beers criteria.
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His exam was only remarkable for bilateral lower extremity edema to the mid-shins.
Laboratory values were notable for a creatinine level of 1.5 mg/dl, with an estimated
creatinine clearance of 39 ml/min. His hemoglobin level was 10.8 g/dl. Creatinine clearance
measured by a 24-hour urine collection was significantly higher than the calculated
clearance (79 ml/min). Echocardiogram demonstrated diastolic dysfunction, but normal
systolic function.
Multidisciplinary treatment planning was undertaken. The patient articulated that his
primary goal of care would be to dance at his granddaughter’s wedding in 3 months. As a
first approach, surgical resection would require hemipelvectomy, a massive procedure
which would have left the patient with only one leg and a large surgical pelvic defect.
Neoadjuvant chemotherapy was proposed to downstage the tumor and potentially allow a
limb-sparing resection. The patient tolerated his first cycle of chemotherapy with carboplatin and doxorubicin quite well, with improvement in his pelvic pain suggestive of
response. He then proceeded with his first dose of methotrexate, which was empirically
dose-reduced to 3.5 g/m2 given concerns about his renal function. Unfortunately, despite the
dose reduction, he developed acute renal failure and prolonged methotrexate clearance. He
required hemodialysis for 3 weeks, ultimately recovering his renal function completely.
Restaging scans following the prolonged hospitalization demonstrated progression of
the mass. The recommendation was to proceed with surgery. By this time, the family
wedding was just a few weeks away, so surgery was delayed. The patient and his wife of
over 50 years danced at the wedding.
The patient then underwent hemipelvectomy. Pathology demonstrated a large osteosarcoma with gross vascular invasion and residual tumor at the margins. His 2-week postoperative course was complicated by delirium. Subsequent to discharge, he was readmitted 1
week later with a hematoma. This was the first of 3 prolonged hospitalizations over the next
3 months with complications including gross hematuria, delirium, depression, pelvic
abscess, urinary tract infection, atrial fibrillation, volume overload, and upper gastrointestinal bleeding.
Radiographic imaging 4 months after his surgery demonstrated a persistent large fluid
collection within the pelvis. Biopsy demonstrated recurrent osteosarcoma. The patient and
his family decided to focus on symptom management and enrolled in hospice. He died
peacefully 2 weeks after his recurrence was diagnosed and 8 months after his initial
diagnosis.
Discussion

This case of a radiation-associated osteosarcoma highlights challenges that will be faced
with the increasing number of older adults with cancer, and of treating those malignancies in
the face of little data while meeting the patient’s goals of care.

Prostate cancer is the most common cancer in men, with more than two thirds of the
prostate cancer-related deaths occurring in men older than 75 years. Men treated with
radiotherapy for prostate cancer are at increased risk for malignancies within the radiation
field, including bladder, rectal and prostatic urethral cancer, with an absolute risk of 4.3% at
15 years of follow-up [5]. In the Surveillance, Epidemiology, and End Results Cancer
Registry, patients with prostate cancer who underwent radiotherapy had a small but
significantly increased risk of second malignancies, including cancers of the bladder and
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rectum as well as sarcomas within the radiation field. For patients who underwent radiation
therapy, the relative risk of second malignancies was increased by 15% at 5 years and 34%
at 10 years [6]. The median interval between radiation and development of a second
malignancy was 10–15 years [6].
Osteosarcoma

Osteosarcoma has a poorer prognosis in elderly patients as compared to younger patients; it is more likely to be diagnosed at a later stage, to be metastatic and to require limb
amputation. The optimal management of osteosarcoma includes neoadjuvant chemotherapy
followed by surgical resection with sufficiently wide surgical margins, and then additional
adjuvant chemotherapy. With this approach, the 5-year disease-free survival rates have
increased to more than 60%, though these improvements have largely been limited to
younger patients [7].
While radiation-associated sarcomas are long-term complications of various types of
cancer, there are only rare reports after prostate cancer. However, with high-dose radiotherapy being widely utilized for the treatment of localized prostate adenocarcinoma,
radiation-induced osteosarcoma should be considered for long-term survivors of prostate
cancer who develop bone lesions within the prior radiation field [8].

Deciding on the optimal treatment for this patient was challenging. Radiation therapy
was not an option, given his previous radiation to the pelvis. Primary surgery was not
initially acceptable to the patient, as it would have resulted in loss of mobility. Thus,
neoadjuvant chemotherapy was felt to provide the best opportunity to downstage the tumor.
However, to decide which chemotherapeutic regimen would provide optimal response while
avoiding serious toxicity was a challenge. A systematic review and meta-analysis showed
that a 3-drug regimen of adriamycin, cisplatin and methotrexate is associated with improved
outcomes over 2-drug regimens [9]. Few patients in these studies were over the age of 40
years, let alone elderly. The decision was ultimately made to proceed with carboplatin,
doxorubicin and high-dose methotrexate. Given concerns about toxicity with high-dose
cisplatin in an older patient, a carboplatin-containing regimen was selected, based on a study
in which the oldest patient was 24 years old [10].
Until recently, medical oncologists have had little data with which to counsel their older
patients on their individual risk of toxicities of chemotherapy. Two recent studies have
explored geriatric assessments as predictors of chemotherapy toxicity. In the Chemotherapy
Risk Assessment Scale for High-Age Patients (CRASH) trial, adding subtle functional
impairments identified with geriatric screening tools to the algorithm predicted toxicity
better than standard oncology clinical and laboratory assessments alone. Specifically,
dependence in IADL predicted hematologic toxicity, while Eastern Cooperative Oncology
Group (ECOG) performance status, cognition and nutrition predicted nonhematologic
toxicity [11]. In the Cancer and Aging Research Group (CARG) study, several domains of
functional impairment identified with geriatric assessment screening tools were associated
with toxicity of chemotherapy. These included hearing impairment, falls, difficulty taking
medications (IADL), limitations in walking one block (IADL), and decreased social activity
[12]. We note that although CARG and CRASH and other studies have also examined ADL
screening tools, there appears to be a ceiling effect. That is, patients who are unable to
perform their own self-care independently are less likely to present for treatment of
advanced malignancy. Therefore, by evaluating IADL, the ability to live alone and maintain a
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household, we might detect more subtle impairments in patients who otherwise appear well.
Our patient was at relatively lower risk based on these models. He tolerated the initial round
of chemotherapy with carboplatin and doxorubicin quite well, but developed acute renal
failure subsequent to methotrexate. While the multifactorial predictive models have
certainly been an advance in the care of older adults, they are still imperfect prognostic tools.
Our patient was functionally intact. Because of his known chronic kidney disease even with
normal measured creatinine clearance, we reduced his methotrexate dose and chose a less
toxic platinum agent. Nonetheless, severe renal toxicity due to chemotherapy started his
decline.
The patient subsequently underwent hemipelvectomy, with a series of postoperative
complications. There are several tools available to predict postoperative complications in
older adults undergoing surgery. The Preoperative Assessment of Cancer in the Elderly
(PACE) was created to evaluate the functional reserve of elderly cancer patients in need of
surgery, and predict their postoperative morbidity and mortality [13]. PACE includes
parameters of the Comprehensive Geriatric Assessment (CGA) such as functional status
(IADL), depression and cognition, but also measures of fatigue, ECOG performance status,
comorbidities and the degree of sickness prior to anesthesia and surgery (American Society
of Anesthesiologists scale). Dependence in IADL, fatigue and abnormal performance status
predicted postoperative complications and prolonged hospital stay. In another study, the
geriatric syndrome of frailty was used. The phenotype of advanced age was defined as a
score summarizing low grip strength (weakness), unintended weight loss, subjective
exhaustion, low self-reported physical activity and slowed walking speed. Higher frailty
scores predicted postoperative complications, length of stay and discharge to a nursing
facility [14].
In the case presented here, the patient had been neither frail nor functionally impaired
prior to chemotherapy, but by the time he presented for surgery, his strength, vitality and
functional status had declined to the point that he was unable to perform his ADL independently. This decline was due both to his prolonged hospitalization for toxicity of
chemotherapy and progression of the sarcoma.
Conclusions

In conclusion, with the aging of the population and increased incidence of cancer with
age, clinicians will face an increasing number of older patients with primary and secondary
malignancies. While there is a growing movement to increase our knowledge base on the
optimal assessment and treatment of older patients with cancer, much remains to be
learned. This case study encompasses many of the issues faced in caring for older adults,
from second malignancies to treating a rare cancer in the absence of data, predicting toxicity
or complications of treatment and meeting the patient’s goals of care.
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